← SynDRA
ABT 737
SynDRA canonical compound SYN0006494 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
| Primary target(s) | BCL2L2 |
| Mechanism of action | BCL inhibitor |
All known targets
Mechanisms of action (all sources)
- BCL inhibitor
- BCL2 INHIBITOR
Cross-references
Synonyms
- Abt-737
- ABT737
- UNII-Z5NFR173NV
- Z5NFR173NV
- 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide
- CHEMBL376408
- C42H45ClN6O5S2
- 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide
- ABT-737
- CHEBI:47575
- RefChem:912152
- DTXCID5022641
- MFCD12756212
- 2yxj
- N3C
- SCHEMBL158942
- GTPL8320
- ABT 737 [WHO-DD]
- N-Benylpiperazine derivative, 2
- SCHEMBL29355185
- BDBM21447
- EX-A056
- HPLNQCPCUACXLM-PGUFJCEWSA-N
- GLXC-04997
- HMS6018M09
- ABT-737?
- NSC758873
- s1002
- compound 2 [PMID 17256834]
- AKOS016003299
- CCG-264769
- CS-0014
- FA16902
- NSC-758873
- NCGC00253562-01
- NCGC00253562-02
- NCGC00253562-03
- NCGC00253562-05
- NCGC00253562-12
Look up ABT 737 in the interactive SynDRA portal →